This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sagent Pharmaceuticals Reports Second Quarter 2012 Financial Results

Stocks in this article: SGNT

Revenue Growth Driven by Products Launched in the Last Twelve Months

Company Revises Guidance for 2012

SCHAUMBURG, Ill., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended June 30, 2012.

Second Quarter 2012 Highlights

  • Revenue increased 32% to $42.7 million driven by products launched in the last twelve months;
  • Reported gross profit increased to $6.5 million, or 15.2% inclusive of $1.2 million of margin from the sale of heparin inventory previously written off through excess inventory reserves;
  • Launched Atracurium Besylate and Irinotecan; and
  • Key manufacturing partner's facility found acceptable by FDA, clearing pathway for multiple product approvals and four to six new product launches during the second half of 2012.

"The second quarter results were in-line with our expectations," said Jeffrey M. Yordon, president, chief executive officer, and chairman of the board of Sagent. "We are confident that our business will continue to strengthen in the second half of the fiscal year, driven by new group purchasing contracts and the anticipated launch of ten to twelve new products over the remainder of 2012."

Financial Results for the quarter ended June 30, 2012

Net revenue for the second quarter of 2012 was $42.7 million, an increase of $10.4 million, or 32%, compared to $32.3 million in the second quarter of 2011. The increase is driven by $14.1 million in revenue from the launch of 36 new codes or presentations of 13 new products since June 30, 2011, partially offset by declines in existing products, primarily due to pricing pressure. Gross profit for the second quarter of 2012 was $6.5 million, or 15.2% of net revenues, compared to $2.7 million, or 8.5% of net revenues, in the second quarter of 2011. Gross profit for the second quarter of 2012 included $1.2 million of margin from the sale of heparin inventory previously written off through excess inventory reserves.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,077.89 +47.68 0.26%
S&P 500 2,090.79 +8.91 0.43%
NASDAQ 4,802.9050 +29.4330 0.62%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs